'problem' is a loaded word. The data is coming in saying that this class of drugs provides potentially massive benefits. If I get a lot of benefit but didn't fully address the root 'problem', I still get a lot of benefit.
Therapies are contingent on being available. That’s uniform. What’s unique about glp-1s is that they are very effective in weight loss and many other things. As compared to alternatives that aren’t.
If we are back at the point of supply chain issues that interrupt GLP-1 for any significant amount of time you're starting to look at issues like we had during covid that are going to have all kinds of other effects.
From my understanding getting the pre-compounded components isn't that difficult, and that India and China are making versions of it now.